Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP865167.RAc-ZmSsgct5FyRqFhlYneLTxX8jz5LXYMr6SHeFOMbXc130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP865167.RAc-ZmSsgct5FyRqFhlYneLTxX8jz5LXYMr6SHeFOMbXc130_assertion type Assertion NP865167.RAc-ZmSsgct5FyRqFhlYneLTxX8jz5LXYMr6SHeFOMbXc130_head.
- NP865167.RAc-ZmSsgct5FyRqFhlYneLTxX8jz5LXYMr6SHeFOMbXc130_assertion description "[The rate of COX-2 high-expression was 53.6% (15/28) and 42.9% (6/14) in HNPCC adenoma and carcinoma; 62.5% (20/32) and 91.7% (22/24) in sporadic adenoma and carcinoma, respectively.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP865167.RAc-ZmSsgct5FyRqFhlYneLTxX8jz5LXYMr6SHeFOMbXc130_provenance.
- NP865167.RAc-ZmSsgct5FyRqFhlYneLTxX8jz5LXYMr6SHeFOMbXc130_assertion evidence source_evidence_literature NP865167.RAc-ZmSsgct5FyRqFhlYneLTxX8jz5LXYMr6SHeFOMbXc130_provenance.
- NP865167.RAc-ZmSsgct5FyRqFhlYneLTxX8jz5LXYMr6SHeFOMbXc130_assertion SIO_000772 21232179 NP865167.RAc-ZmSsgct5FyRqFhlYneLTxX8jz5LXYMr6SHeFOMbXc130_provenance.
- NP865167.RAc-ZmSsgct5FyRqFhlYneLTxX8jz5LXYMr6SHeFOMbXc130_assertion wasDerivedFrom befree-2016 NP865167.RAc-ZmSsgct5FyRqFhlYneLTxX8jz5LXYMr6SHeFOMbXc130_provenance.
- NP865167.RAc-ZmSsgct5FyRqFhlYneLTxX8jz5LXYMr6SHeFOMbXc130_assertion wasGeneratedBy ECO_0000203 NP865167.RAc-ZmSsgct5FyRqFhlYneLTxX8jz5LXYMr6SHeFOMbXc130_provenance.